| Code | CSB-RA006163MB17HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to YH-001, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated protein 4), a critical immune checkpoint receptor expressed primarily on T cells. CTLA4 functions as a negative regulator of T cell activation by competing with CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, thereby dampening immune responses and maintaining immune homeostasis. Dysregulation of CTLA4-mediated signaling plays a significant role in autoimmune diseases, transplant rejection, and tumor immune evasion, making it a pivotal target in immunology research and therapeutic development.
YH-001 serves as the reference antibody for this biosimilar product, providing researchers with a cost-effective alternative for investigating CTLA4 biology and immune regulation mechanisms. This antibody is valuable for studies examining T cell exhaustion, immune checkpoint pathways, autoimmunity, and cancer immunology. It supports experimental investigations into CTLA4's role in immune tolerance, T cell co-stimulation blockade, and the development of immunomodulatory strategies.
There are currently no reviews for this product.